Cephalexin is effective against staph infections, but only those caused by methicillin-sensitive Staphylococcus aureus (MSSA). It will not work against MRSA. For common staph skin infections like cellulitis, folliculitis, and impetigo, cephalexin is one of the most frequently prescribed oral antibiotics and is FDA-approved specifically for skin infections caused by S. aureus.
Why It Works Against Some Staph but Not Others
Cephalexin is a first-generation cephalosporin, meaning it belongs to the same broad family as penicillin. It kills bacteria by disrupting their ability to build cell walls, which causes the bacterial cells to break apart. This mechanism works well against MSSA, the strain of staph that hasn’t developed resistance to this class of drugs.
MRSA, on the other hand, has a genetic change that makes its cell wall proteins unrecognizable to cephalexin. The drug simply can’t latch on. If your infection is caused by MRSA, cephalexin won’t help, and your provider will need to choose a different antibiotic entirely. This is why doctors sometimes swab an infected wound or abscess for culture before prescribing. Knowing whether the staph is MSSA or MRSA determines whether cephalexin is a good fit.
Infections Where Cephalexin Is Commonly Used
The FDA approves cephalexin for skin and skin-structure infections caused by S. aureus, as well as bone infections involving staph. In practice, it’s prescribed for a wider range of MSSA infections, including:
- Cellulitis: spreading skin redness, warmth, and swelling
- Folliculitis: infected hair follicles
- Impetigo: crusty, blistering skin sores common in children
- Mastitis: breast tissue infection, often during breastfeeding
- Bone infections (osteomyelitis): though it’s typically not the first-choice drug for bone infections and is more often used as a step-down after initial treatment with stronger antibiotics
A study of patients with MSSA-caused spinal bone infections found an 87% treatment success rate when patients were switched to oral cephalexin after an initial course of intravenous antibiotics. Cephalexin has also shown effectiveness against MSSA skin and bone infections in children.
What to Expect During Treatment
For most staph skin infections, adults take between 1,000 and 4,000 mg per day, split into multiple doses. A typical course lasts about 7 days, though your provider may adjust this depending on how severe the infection is and how quickly it responds.
You should start feeling better within 2 to 3 days. If you don’t notice any improvement by then, or if the infection seems to be getting worse at any point, that’s a signal to contact your provider. The infection may be resistant to cephalexin, or you may need a different approach.
Finishing the full course matters even after symptoms improve. Stopping early can leave surviving bacteria behind, increasing the chance of the infection returning or developing resistance.
Dosing for Children
Children’s doses are calculated by weight. Recent research on children with bone and joint infections found that cephalexin at 25 mg per kilogram of body weight, given three times daily (with a maximum of 750 mg per dose), achieved the drug levels needed to reliably kill MSSA. Higher doses may be used depending on the severity and type of infection, with some protocols going up to 50 mg/kg per dose.
Common Side Effects
Cephalexin is generally well tolerated. The most frequent side effects are digestive: nausea, diarrhea, stomach discomfort, and occasionally vomiting. These tend to be mild. Taking it with food can help settle your stomach without significantly affecting how well the drug is absorbed.
More serious reactions are uncommon. Allergic responses like rash or hives can occur, particularly in people with known antibiotic sensitivities. Prolonged courses can sometimes lead to yeast infections or, rarely, a type of severe diarrhea caused by C. difficile overgrowth in the gut.
Penicillin Allergy and Cephalexin
If you’ve been told you’re allergic to penicillin, you may have heard that cephalosporins are off-limits too. Older estimates placed the cross-reactivity rate as high as 8 to 10%, but those numbers came from flawed, self-reported surveys. More recent and rigorous studies paint a very different picture.
In one study, 153 patients with a documented penicillin allergy received a first-generation cephalosporin, and only one had a minor reaction (hives). Another reviewed 413 penicillin-allergic patients given a cephalosporin with just one possible reaction. A 2021 study went further: out of 452 penicillin-allergic patients who underwent formal allergy skin testing for cephalosporins, zero tested positive. True cross-reactivity appears to be well under 1%, and reactions that do occur tend to be mild. If you have a penicillin allergy listed in your chart, it’s worth discussing with your provider rather than assuming cephalexin is automatically unsafe.
When Cephalexin Won’t Be Enough
The biggest limitation is MRSA. Community-acquired MRSA is common in skin infections, especially abscesses. If you have a large, pus-filled boil or an infection that isn’t improving on cephalexin, MRSA may be the reason. Providers typically switch to antibiotics with MRSA coverage in those situations.
Cephalexin also has limits for deeper or more severe infections. It’s an oral medication, so it depends on your gut absorbing enough drug to reach effective levels in the blood. For serious bloodstream infections, infections around heart valves, or deep abscesses, intravenous antibiotics are usually needed first, with cephalexin sometimes used afterward to finish the course once the infection is under control.
For straightforward MSSA skin infections, though, cephalexin remains one of the most reliable and commonly used options. It’s inexpensive, widely available, and has decades of clinical use supporting its effectiveness.